Implantica AG (FRA:8IM1) EV-to-OCF: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8IM1 Implantica AG FRA:8IM1
34 GF Score
Price €5.36
View Full Analysis

What is Implantica AG EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Implantica AG's Enterprise Value is €0.00 Mil. Implantica AG does not have enough years/quarters to calculate its Cash Flow from Operations for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Implantica AG's EV-to-OCF at this moment.

The historical rank and industry rank for Implantica AG's EV-to-OCF or its related term are showing as below:

FRA:8IM1's EV-to-OCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.91
* Ranked among companies with meaningful EV-to-OCF only.

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-31), Implantica AG's stock price is €5.36. Implantica AG does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Implantica AG's PE Ratio (TTM) at this moment.

Implantica AG  (FRA:8IM1) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Implantica AG's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.36/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Implantica AG EV-to-OCF Related Terms

Implantica AG EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Implantica AG's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Implantica AG EV-to-OCF Chart

Implantica AG Annual Data
Trend
EV-to-OCF

Implantica AG Semi-Annual Data
EV-to-OCF
FRA:8IM1
34GF Score
Implantica AG FRA:8IM1
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Implantica AG EV-to-OCF Calculation

Implantica AG's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.000/
=

Implantica AG Business Description

Comparable Companies
Other Exchanges IMP A SDB:Sweden
Address Aeulestrasse 15, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected product pipeline based partly on its two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body, and communicate with the caregiver at a distance, and a wireless energising platform designed to power remote-controlled implants wirelessly through intact skin.
34GF Score

Get the complete analysis for FRA:8IM1

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.36
Price